Gilead Sciences Inc (GILD)

81.37
NASDAQ : Health Care
Prev Close 81.52
Day Low/High 81.22 / 82.00
52 Wk Low/High 76.67 / 111.11
Avg Volume 10.71M
Exchange NASDAQ
Shares Outstanding 1.32B
Market Cap 107.58B
EPS 12.40
P/E Ratio 7.19
Div & Yield 1.88 (2.30%)

Latest News

Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note

Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note

Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.

Allergan's Boldness may not be Limited to Tobira Deal

Allergan's Boldness may not be Limited to Tobira Deal

The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.

Gilead Terminates Phase 2/3 Study Of GS-5745 In Patients With Ulcerative Colitis

Gilead Terminates Phase 2/3 Study Of GS-5745 In Patients With Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely active...

Gilead Sciences (GILD) Stock Lower, Gabelli: Allergan Could Be Buyer

Gilead Sciences (GILD) Stock Lower, Gabelli: Allergan Could Be Buyer

Gabelli analysts say Gilead Sciences (GILD) could be the next possible takeover target by Allergan (AGN), as the company has a 'deep pipeline' of NASH drugs.

Here's a Reason Why Gilead (GILD) Stock Is Gaining Today

Here's a Reason Why Gilead (GILD) Stock Is Gaining Today

Gilead (GILD) stock was climbing Tuesday afternoon after Allergan (AGN) said it would buy Tobira (TBRA).

Gilead Is in Breakout Mode

Gilead Is in Breakout Mode

Shares of Gilead Sciences are surging today. Here's how to trade the stock from here.

Know When and How Buybacks Are Worth Buying

Know When and How Buybacks Are Worth Buying

Buybacks may alert investors to a great opportunity or worthless paperwork.

You've Got the Brains, I've Got the Book, Let's Make Lots of Money

You've Got the Brains, I've Got the Book, Let's Make Lots of Money

Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.

Gilead: Horse of a Different, uh, Color

Gilead: Horse of a Different, uh, Color

The once-mighty biotech has fallen, but entry opportunities will surface.

Gilead (GILD) Stock Down, Jefferies: $5 Billion Debt Offering Suggests 'Imminent' Deal

Gilead (GILD) Stock Down, Jefferies: $5 Billion Debt Offering Suggests 'Imminent' Deal

Jefferies analysts say Gilead's (GILD) $5 billion debt offering could suggest that the company plans to seek out one or several acquisitions, possibly in the orphan diseases sector.

Gilead Prices $5 Billion Of Senior Unsecured Notes

Gilead Prices $5 Billion Of Senior Unsecured Notes

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five tranches: ...

Gilead's Pipeline, Maligned by Investors, Still Packed With 4Q Clinical Trial Readouts

Gilead's Pipeline, Maligned by Investors, Still Packed With 4Q Clinical Trial Readouts

Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.

Will Gilead Sciences (GILD) Stock Be Affected by Lower Price Target?

Will Gilead Sciences (GILD) Stock Be Affected by Lower Price Target?

Credit Suisse trimmed its price target on shares of Gilead Sciences (GILD) to $95 in a note on Wednesday.

Buy Gilead and Wait for the Rebound

Buy Gilead and Wait for the Rebound

Gilead is a cheap stock with solid turnaround potential and a healthy dividend.

Gilead Sciences (GILD) Stock Up, CEO Milligan Talks M&A Strategy

Gilead Sciences (GILD) Stock Up, CEO Milligan Talks M&A Strategy

Gilead Sciences (GILD) CEO John Milligan said on Monday that the company won't rule out a large deal but would prefer a series of smaller ones.

3 Stocks That Could Still Rally

It's been a nasty decline, but if we rally, these three have best charts.

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?

Upcoming Dividend Must-Own Dates

From Altria to Western Union, these 21 companies have must-own dates over the next week.

Will Gilead Sciences (GILD) Stock Be Helped by New China Executive?

Will Gilead Sciences (GILD) Stock Be Helped by New China Executive?

Gilead Sciences (GILD) said on Friday that it hired former Roche (RHHBY) executive Rogers Luo as VP and general manager of its Chinese commercial operations.

Dive Safely Into These 12 Dividend Payers

Dive Safely Into These 12 Dividend Payers

If and when interest rates go up, this basket of stocks should continue to do well.

2 Hot Biotech Stocks Trading at Bargain Prices Right Now

2 Hot Biotech Stocks Trading at Bargain Prices Right Now

In the rising biotech sector, it's hard to find solid growth stocks that are also cheap. But we've done the homework for you.

Will Gilead Sciences (GILD) Stock Be Hurt by Bearish Piper Jaffray Note?

Will Gilead Sciences (GILD) Stock Be Hurt by Bearish Piper Jaffray Note?

Piper Jaffray said Gilead Sciences (GILD) could be forced to guide full-year 2016 revenue lower than prior estimates.

Gilead Sciences To Present At Three Upcoming Investor Conferences In September

Gilead Sciences To Present At Three Upcoming Investor Conferences In September

Gilead Sciences, Inc. (Nasdaq: GILD) today announced webcasts from three upcoming investor conferences: Citi's 11 th Annual Biotech Conference, the 2016 Wells Fargo Healthcare Conference and the Morgan Stanley Global...

Stocks Turn Mixed as Services Activity Sees Slowest Growth Since 2010

Stocks Turn Mixed as Services Activity Sees Slowest Growth Since 2010

Stocks hold mixed by mid-morning Tuesday after U.S. services activity last month declines more than expected.

Jim Cramer -- Gilead Should Be Manufacturing Mergers, Too

Jim Cramer -- Gilead Should Be Manufacturing Mergers, Too

Gilead has the financial firepower to do a merger or acquisition, which would benefit its shareholders, Cramer says.

U.S. Stocks Gain Steam Despite Declines in Oil; GE Acquires 3D Printing Companies

U.S. Stocks Gain Steam Despite Declines in Oil; GE Acquires 3D Printing Companies

U.S. stocks rose Tuesday, as oil prices added one percent on hopes of a production freeze among the world's biggest oil producers.

Gilead Sciences (GILD) Stock Gains, Jefferies Raises Rating

Gilead Sciences (GILD) Stock Gains, Jefferies Raises Rating

Gilead Sciences (GILD) stock was upgraded at Jefferies Tuesday morning to 'buy' from 'hold.'

Stock Futures Edge Higher as Wall Street Mulls Fed's Next Move

Stock Futures Edge Higher as Wall Street Mulls Fed's Next Move

Stock futures edge higher in the return from the long Labor Day weekend as markets continue to mull over the Federal Reserve's next big move.